Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with Dose-Dense High-Dose Chemotherapy and ASCT for High-Risk DLBCL
NCT00556127Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Jun 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by GIMEMA. Primary endpoint: Failure-free survival at 3 years. Started Jun 2002; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00556127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556127.